Containing Discrete Coated Particles Pellets, Granules, Or Beads Patents (Class 424/458)
  • Patent number: 8062663
    Abstract: Methods and compositions for enhancing transdermal delivery of a bioactive agent. The method contains the step of applying to a skin tissue an effective amount of a composition comprising: (a) a drug vehicle; (b) a bioactive agent encapsulated within the drug vehicle; (c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the drug vehicle; and (d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: November 22, 2011
    Assignee: National Health Research Instittues
    Inventors: Yu-Jing Wang, Yu-Chao Wang, Yi-Ting Wu, Lin-Ai Tai, Leu-Wei Lo, Chung-Shi Yang
  • Publication number: 20110280939
    Abstract: The present invention relates to an oral particle including pseudoephedrine hydrochloride and cetirizine dihydrochloride, which primarily includes a nucleus having a diameter ranging 25˜40 mesh, a pseudoephedrine-hydrochloride layer coated outside the nucleus with a coating solution composed of pseudoephedrine hydrochloride, a binder, a lubricant and pure water/alcohol, a release-control layer coated outside the pseudoephedrine-hydrochloride layer, and a cetirizine-dihydrochloride layer coated outside the release-control layer with a coating solution composed of cetirizine dihydrochloride, a binder, a lubricant and pure water/alcohol. Accordingly, by distributing pseudoephedrine hydrochloride and cetirizine dihydrochloride into hundreds of the particles and controlling the dissolution rate with the release-control layer, the particles can perform good absorption efficiency, and quick, stable and long-term edicinal effect.
    Type: Application
    Filed: July 5, 2011
    Publication date: November 17, 2011
    Applicant: EVEREST PHARM. INDUSTRIAL CO., LTD.
    Inventor: TA-PING LIAO
  • Publication number: 20110262535
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Application
    Filed: July 1, 2011
    Publication date: October 27, 2011
    Applicant: Vivus, Inc.
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Publication number: 20110229566
    Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.
    Type: Application
    Filed: August 22, 2009
    Publication date: September 22, 2011
    Inventors: Yatendra Kumar Gupta, Girish Kumar Jain, Munish Talwar, Manoj Mashalkar
  • Publication number: 20110223247
    Abstract: Disclosed is a pharmaceutical composition for release control comprising a plurality of particles for release control. The plurality of particles for release control comprise a core material containing methylphenidate and a polymer coating layer for release control formed on the core material. The plurality of particles for release control are divided into two or more groups based on the average thickness of the polymer coating layer for release control. The particle groups are identical in terms of the composition of the polymer in the polymer coating layer, but are different in terms of the average thickness of the coated layer. The pharmaceutical composition for release control according to the present invention may control the release pattern of methylphenidate contained in the core material as desired, and can be used as an oral formulation in a variety of forms such as orally disintegrating tablets, etc.
    Type: Application
    Filed: November 6, 2009
    Publication date: September 15, 2011
    Applicant: SAMYANG CORPORATION
    Inventors: Sang Yeob Park, Hojin Chung, Chaul Min Pai
  • Patent number: 7999005
    Abstract: An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: August 16, 2011
    Assignee: Schering-Plough Animal Health Corporation
    Inventors: Chung Shih, Thomas J. Kennedy, Peter James Knight, Daniel S. Robins, Zezhi Jesse Shao
  • Publication number: 20110189273
    Abstract: Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.
    Type: Application
    Filed: December 2, 2010
    Publication date: August 4, 2011
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Gayatri Sathyan, Kavita Vermani, Gangadhara Ganapati, Michael Coffee, Efraim Shek, Ashok Katdare
  • Publication number: 20110123613
    Abstract: Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially surrounding the inner core bead, and an outer coating substantially surrounding the intermediate coating comprising a pH independent polymer. Also provided is a pharmaceutical formulation comprising two bead populations wherein each of the first and second bead populations have a different drug release profile. Also provided is a method of preparing an extended release dosage composition comprising one or more bead populations.
    Type: Application
    Filed: December 23, 2010
    Publication date: May 26, 2011
    Applicant: MYLAN TECHNOLOGIES INC.
    Inventors: Pavan Bhat, Sarat C. Chattaraj, Andrew A. Shaw
  • Publication number: 20110117192
    Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.
    Type: Application
    Filed: April 17, 2009
    Publication date: May 19, 2011
    Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
  • Patent number: 7931915
    Abstract: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: April 26, 2011
    Assignee: Andrx Pharmaceuticals, LLC
    Inventors: Manesh Dixit, Xiu-Xiu Cheng, Avinash Nangia, Chih Ming Chen
  • Publication number: 20110091542
    Abstract: A biodegradable, multi-layered controlled release gastroretentive baclofen or R-baclofen dosage form which is optionally divided into a first dosage of baclofen or R-baclofen for immediate release and a second dosage of baclofen or R-baclofen for controlled release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide fast onset of baclofen or R-baclofen activity with prolonged absorption and minimal undesirable side effects.
    Type: Application
    Filed: June 9, 2010
    Publication date: April 21, 2011
    Inventors: Nadav Navon, Julia Shvetz, Eytan Moor, David Kirmayer, Elena Kluev, Shuher Masri, Giora Carni, Zeev Weiss
  • Patent number: 7919483
    Abstract: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: April 5, 2011
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
  • Publication number: 20110064804
    Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.
    Type: Application
    Filed: April 9, 2010
    Publication date: March 17, 2011
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz
  • Publication number: 20110064803
    Abstract: The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of osteoporosis. The invention also relates to a controlled release composition comprising a vitamin K2 or a nanoparticulate vitamin K2 that in operation delivers the drug in a pulsed or multi-modal manner for the prevention and treatment of osteoporosis.
    Type: Application
    Filed: May 9, 2006
    Publication date: March 17, 2011
    Applicant: ELAN PHARMA INTERNATIONAL LIMITED.
    Inventors: John G. Devane, Paul Stark, Niall M.N. Fanning, Gurvinder Singh Rekhi, Gary Liversidge, Scott Jenkins
  • Patent number: 7858118
    Abstract: An oral Tramadol-containing pharmaceutical composition suitable for once daily administration, which contains an amount of Tramadol or a pharmaceutically acceptable salt thereof, providing in vivo, a time of Tramadol peak plasma concentration (Tmax) of greater than 10 hours, and peak Tramadol plasma concentration (Cmax) which are less than three times the plasma concentration obtained 24 hours after administration (C24h) of a single dose of the composition.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: December 28, 2010
    Assignee: Galephar Pharmaceutical Research, Inc.
    Inventors: Arthur M. Deboeck, Francis Vanderbist, Antonio Sereno
  • Patent number: 7842311
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
    Type: Grant
    Filed: October 21, 2003
    Date of Patent: November 30, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Publication number: 20100270183
    Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
    Type: Application
    Filed: July 8, 2010
    Publication date: October 28, 2010
    Applicant: EURAND PHARMACEUTICALS LTD
    Inventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
  • Publication number: 20100272797
    Abstract: Disclosed herein is a pharmaceutical composition for treating hepatitis C virus infection comprising an HMG-CoA reductase inhibitor and bile acid. More specifically, disclosed are a pharmaceutical composition for treating hepatitis C vims infection comprising fluvastatin or a pharmaceutically acceptable salt thereof along with ursodeoxycholic acid and a preparation method thereof.
    Type: Application
    Filed: October 10, 2008
    Publication date: October 28, 2010
    Applicant: HANALL PHARMACEUTICAL COMPANY, LTD.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jun Young Lee
  • Publication number: 20100266684
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Application
    Filed: April 9, 2010
    Publication date: October 21, 2010
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 7815937
    Abstract: The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflash particles and an excipient mass. A preferred excipient mass according to the invention contains a directly compressible inorganic salt; a cellulose derivative or a combination of a directly compressible inorganic salt and a cellulose derivative. Preferably, the liquiflash particles and the excipient mass are combined in proportions such that the active ingredient remains substantially within the microspheres when the composition is compressed to obtain a dosage form having a hardness of 20 to 50 N. The compositions of the invention allow for the fabrication of oral dosages having improved hardness and friability.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: October 19, 2010
    Assignee: Biovail Laboratories International SRL
    Inventors: Naima Mezaache, Steven E. Frisbee, Patrick B. Woodall, Mark R. Herman, Djelila Mezaache
  • Patent number: 7815938
    Abstract: A film coating composition suitable for use in coating pharmaceutical formulations to provide modified release comprising a dispersion which includes: a) an acrylic polymer, b) a vinyl acetate polymer, and c) a water-containing liquid. The film coat is useful for the achievement of modified release from pharmaceutical formulations such as tablets, pellets, etc.
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: October 19, 2010
    Assignee: AstraZeneca AB
    Inventors: Jan-Erik Löfroth, Staffan Schantz, Anders Welin, Lars Johan Pontus de Verdier Hjärtstam
  • Publication number: 20100260838
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Application
    Filed: April 9, 2010
    Publication date: October 14, 2010
    Applicant: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 7807195
    Abstract: The present invention relates to an extended release once daily pharmaceutical formulation comprising venlafaxine hydrochloride and pharmaceutically acceptable excipients. More particularly, the present invention relates to an extended release composition in the form of mini-tablets which are incorporated in hard gelatin capsules.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: October 5, 2010
    Assignee: Alembic Limited
    Inventors: Sampad Bhattacharya, Rajesh Kshirsagar, Mayank Joshi, Sandeep Pandita
  • Patent number: 7790705
    Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: September 7, 2010
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
  • Patent number: 7771750
    Abstract: A once a day bupropion hydrochloride formulation is disclosed.
    Type: Grant
    Filed: March 1, 2005
    Date of Patent: August 10, 2010
    Assignee: Andrx Pharmaceuticals, LLC
    Inventors: Boyong Li, Avinash Nangia, Chih Ming Chen, Xiu Xiu Cheng
  • Patent number: 7767708
    Abstract: An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: August 3, 2010
    Assignee: Schering-Plough Animal Health Corp.
    Inventors: Shih Chung, Thomas J. Kennedy, Peter James Knight, Daniel S. Robins, Zezhi Jesse Shao
  • Publication number: 20100189782
    Abstract: The present invention provides compositions comprising carisoprodol or pharmaceutically acceptable salts, esters or derivatives thereof. In certain embodiments, the invention provides pharmaceutical compositions comprising the skeletal muscle relaxant carisoprodol and one or more additional active agents, such as one or more nonsteroidal antiinflammatory drugs (NSAIDs). The invention further provides methods of use of such compositions in preventing, alleviating and/or treating musculoskeletal pain, muscle spasms, or other non-malignant painful conditions including methods in which the circulating levels of the active pharmaceutical form of carisoprodol are controlled by use of extended- or controlled-release formulations or by strict control of dosage regimen, so as to reduce the level of somnolence observed with other muscle relaxant compositions.
    Type: Application
    Filed: March 3, 2008
    Publication date: July 29, 2010
    Inventors: Gul Balwani, Harry J. Sacks, Bryan A. Roecklein, Benjamin Johns
  • Patent number: 7754239
    Abstract: The present invention relates to a capsule comprising a core and at least one envelope comprising at least one film-forming polymer, characterized in that it exhibits a total solubilization time for its envelope of less than or equal to 85 s, according to a test A, preferably less than or equal to 80 s, more preferably less than or equal to 70 s. The invention also relates to the method of producing said capsule, and also to the products comprising said capsule, such as the food, pharmaceutical, oral hygiene or cosmetic products.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: July 13, 2010
    Assignee: V. Mane Fils S.A.
    Inventors: Jean Mane, Pierre Grimault, Jean-Michel Hannetel
  • Patent number: 7749532
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: July 6, 2010
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Patent number: 7749537
    Abstract: A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, resulting from mixing at least one excipient with the pre-blend mixture, form a blend suitable for direct compression and compressing the blend to form the tablet. One way of achieving the first mixing effort is to pre-blend for an extended period of time. The method allows for directly compressing the blend without the need for a granulation step or roller compression. One such active pharmaceutical ingredient susceptible to tackiness is ibuprofen.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: July 6, 2010
    Assignee: SCOLR Pharma, Inc.
    Inventors: Michael Hite, Cathy Federici, Alan Brunelle, Stephen Turner
  • Patent number: 7744922
    Abstract: The present invention relates to a capsule comprising a core and at least one envelope comprising at least one film-forming polymer, characterized in that it exhibits a total solubilization time for its envelope of less than or equal to 85 s, according to a test A, preferably less than or equal to 80 s, more preferably less than or equal to 70 s. The invention also relates to the method of producing said capsule, and also to the products comprising said capsule, such as the food, pharmaceutical, oral hygiene or cosmetic products.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: June 29, 2010
    Assignee: V. Mane Fils S.A.
    Inventors: Jean Mane, Pierre Grimault, Jean-Michel Hannetel
  • Patent number: 7740881
    Abstract: Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. of from about 12.5% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours, and greater than about 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of said opioid analgesic obtained in-vivo occurs from about 2 to about 8 hours after administration of the dosage form.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: June 22, 2010
    Assignee: Purdue Pharma LP
    Inventors: Richard Sackler, Robert Kaiko, Paul Goldenheim
  • Publication number: 20100151015
    Abstract: The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a core comprising melperone and a controlled-release coating. The present invention is also directed to pharmaceutical dosage forms comprising melperone, including orally disintegrating tablets, conventional tablets, and capsules, and methods for their preparation.
    Type: Application
    Filed: December 16, 2009
    Publication date: June 17, 2010
    Inventors: Gopi M. Venkatesh, Phillip J. Stevens, Jin-Wang Lai
  • Patent number: 7727553
    Abstract: The present invention provides oral preparations with good disintegration containing a slightly water-soluble active ingredient, which comprise a mixture of a solid formed product (e.g. a granule) and a second disintegrant wherein said solid formed product comprises a slightly water-soluble active ingredient, a first disintegrant and a water-soluble excipient which is formed by using a water-soluble polymer binder; or comprises a solid formed product prepared from a slightly water-soluble active ingredient, a disintegrant and a sugar alcohol by using a water-soluble polymer binder. When orally administered, these oral preparations exhibit excellent dissolution characteristics of the active ingredient in the digestive tract, and further, these preparations can show equivalent dissolution profile even at different amounts of the active ingredient, and thus enable the selection of the most suitable medicament for each patient, which makes these preparations highly useful in the clinical field.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: June 1, 2010
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventor: Kazuyuki Fujihara
  • Publication number: 20100086588
    Abstract: Disclosed are methods for treating gastrointestinal disorders, e.g., Crohn's disease, ulcerative colitis, and diverticular disease, with a granulated mesalamine formulation. Some formulations use granulated mesalamine in capsule form. Also included are methods to extend remission of ulcerative colitis by administration of a once-daily dosage of granulated mesalamine.
    Type: Application
    Filed: October 2, 2009
    Publication date: April 8, 2010
    Applicant: SALIX PHARMACEUTICALS, LTD.
    Inventor: William Forbes
  • Patent number: 7691408
    Abstract: The invention relates to a heat-sensitive composition in liquid form, containing: an organic hydrophobic liquid; an organogelling substance, the molecules of which can be bound to one another by low energy linkages; and a bioactive substance, which switches to organogel form upon coming into contact with a physiological fluid during the administration thereof into an animal body, in particular, a human.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: April 6, 2010
    Assignees: Ethypharm, Universite De Montreal
    Inventors: Jean-Christophe Leroux, Anne-Claude Couffin-Hoarau
  • Publication number: 20100068267
    Abstract: The invention provides methods of treating a cardiovascular disease comprising administering a sustained release formulation of hydralazine hydrochloride and at least one of isosorbide dinitrate and/or isosorbide mononitrate in therapeutically effective dosage of each of the aforementioned compounds.
    Type: Application
    Filed: September 22, 2009
    Publication date: March 18, 2010
    Applicant: NITROMED, INC.
    Inventors: Joseph LOSCALZO, Joseph A. VITA, Michael D. LOBERG, Manuel WORCEL
  • Publication number: 20100052900
    Abstract: A system for monitoring ingestion of medicine (21) comprises forming a digestible radio frequency identification (RFID) tag (10). The RFID tag is attached to the medicine. The RFID tag and medicine are ingested. A signal from the RFID tag is monitored.
    Type: Application
    Filed: November 9, 2009
    Publication date: March 4, 2010
    Inventors: Edward Covannon, John R. Squilla, Donna K. Rankin-Parobek, Eugene R. Rinas, Nelson A. Blish
  • Publication number: 20100055177
    Abstract: Provided are modified release levetiracetam compositions, and processes for preparing them.
    Type: Application
    Filed: August 28, 2009
    Publication date: March 4, 2010
    Inventors: Dafna Arieli, Orly Grinberg, Roey Solomonovich
  • Publication number: 20100047341
    Abstract: The present invention relates to a functional combination preparation comprising a dihydropyridine-based calcium channel blocker such as amlodipine and an ARB (Angiotensin-2 receptor blocker) such as losartan. In particular, the present invention relates to a chronotherapeutical combination pharmaceutical formulations with controlled-release for the prevention or treatment of cardiovascular disease, which is formulated in accordance with xenobiotics and chronotherapy for enabling the two drugs to be chronotherapeutically released, thereby improving the therapeutic activity as compared to the co-administration of each drug in the form of a single pill, while reducing side effects and maintaining the therapeutic activity as high as possible at the time of day when the risk of a complication of cardiovascular disease is highest.
    Type: Application
    Filed: October 10, 2007
    Publication date: February 25, 2010
    Applicant: HANALL PHARMACEUTICAL CO., LTD.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja-Seong Koo, Sang Ouk Sun
  • Publication number: 20100047342
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Application
    Filed: July 30, 2009
    Publication date: February 25, 2010
    Applicant: ADAMAS PHARMACEUTICALS, INC.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Publication number: 20100040680
    Abstract: A multiparticulate oral pharmaceutical composition that contains a plurality of delayed release coated selective serotonin and norepinephrine reuptake inhibitor particles.
    Type: Application
    Filed: August 15, 2008
    Publication date: February 18, 2010
    Inventors: Felix Lai, Richard Ting, Christopher A. Simpson, Victoria Kellogg, Sibel Ucpinar
  • Patent number: 7662407
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: February 16, 2010
    Assignee: Biovail Laboratories International S.R.L.
    Inventors: Werner Oberegger, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
  • Patent number: 7658939
    Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: February 9, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
  • Publication number: 20100021537
    Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
    Type: Application
    Filed: October 9, 2009
    Publication date: January 28, 2010
    Inventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
  • Publication number: 20090238867
    Abstract: Nanoparticulate compositions comprising anidulafungin are described, as well as methods of making such compositions. Also described are methods for treatment of fungal infections.
    Type: Application
    Filed: December 9, 2008
    Publication date: September 24, 2009
    Inventors: Scott Jenkins, Gary Liversidge, Deborah Neville
  • Publication number: 20090214640
    Abstract: The present invention relates to a delayed release pharmaceutical oral dosage form and method of making same. The delayed release dosage form comprises one or more active ingredients within a granulated composition, which further comprises one or more excipients selected from the group of solid aliphatic alcohols, fatty acid esters, mixtures of esters of saturated fatty alcohols and saturated fatty acids, natural waxes, synthetic waxes, hydrogenated castor oil, hydrogenated vegetable oil, gums, and mixtures thereof; and one or more polymers or copolymers exhibiting a pH-dependent solubility. The present invention also related to method of making these delayed release dosage form.
    Type: Application
    Filed: March 3, 2006
    Publication date: August 27, 2009
    Inventors: Pompilia Szabo, Horst Zerbe
  • Patent number: 7575743
    Abstract: Compositions and methods are provided for treatment of cartilage defects in animals and humans. The compositions of the invention include synovial tissue, synovial cells and matrices containing synovial (or cambium) tissue or cells for use in filling a cartilage defect. The matrix and synovial tissue or cell preparations may also contain a proliferation agent, transforming factor or other active agents to promote healing. A controlled-release delivery system may be used to administer the transforming factor. The compositions of the invention also include a synovial covering membrane or devitalized fascial sheet for covering the cartilage defect. The methods of this invention are those in which a minimally invasive surgical intervention is performed to remove a small portion of synovial membrane from a joint. Portions of the synovial membrane, or cells expanded in vitro, are implanted alone or within a matrix, into the defect site, where they produce new cartilage tissue and repair the defect.
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: August 18, 2009
    Assignee: Orthogene, Inc.
    Inventor: Ernst B. Hunziker
  • Patent number: RE41148
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: February 23, 2010
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Edward M. Rudnic, Charlotte M. McGuinness
  • Patent number: RE42096
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one of a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: February 1, 2011
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Rong-Kun Chang, Donald J. Treacy, Charlotte M. McGuiness, Edward M. Rudnic